Orchestra BioMed Holdings (OBIO) Change in Receivables (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported Change in Receivables of -$11000.0 for Q1 2026, down 266.67% year-over-year from $6600.0 in Q1 2025, and down 125.58% on a QoQ basis from $43000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of Change in Receivables data on file, last reported at -$11000.0 in Q1 2026.
- Quarterly Change in Receivables fell 266.67% year-over-year to -$11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5000.0 (down 171.43% YoY) and the FY2025 annual result came in at $3000.0, up 113.64% from the prior year.
- Change in Receivables eased to -$11000.0 in Q1 2026 per OBIO's latest filing, from $43000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $95000.0 in Q2 2023 and bottomed at -$85000.0 in Q3 2023.
- The 5-year median for Change in Receivables is -$4500.0 (2025), against an average of -$3250.0.
- Peak annual rise in Change in Receivables reached 9400.0% in 2023, while the deepest fall reached 631.25% in 2023.
- Tracing OBIO's Change in Receivables over 5 years: stood at $16000.0 in 2022, then slipped by 18.75% to $13000.0 in 2023, then tumbled by 392.31% to -$38000.0 in 2024, then soared by 213.16% to $43000.0 in 2025, then plunged by 125.58% to -$11000.0 in 2026.
- Per Business Quant, the three latest OBIO Change in Receivables figures stand at -$11000.0 (Q1 2026), $43000.0 (Q4 2025), and -$31000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -11,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11,000.00 |
| Mar 31, 2026 | -11,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Sep 30, 2025 | -31,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Dec 31, 2024 | -38,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Mar 31, 2024 | -32,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Dec 31, 2023 | 13,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Jun 30, 2023 | 95,000.00 |
| Jun 30, 2023 | 95,000.00 |
| Mar 31, 2023 | -20,000.00 |
| Mar 31, 2023 | -20,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | -42,000.00 |
| Mar 31, 2022 | -42,000.00 |